Citations

Showing 10 of 108104 citations.

Systemic Therapy of Metastatic Pancreatic Adenocarcinoma: Current Status, Challenges, and Opportunities
Chakrabarti, Sakti , Kamgar, Mandana , Mahipal, Amit , Mahipal, Amit , Chakrabarti, Sakti

Mayo Clinic

Cancers | May 24, 2022 | Volume: 14 | Issue: 11 | Pages: 2588

10.3390/cancers14112588 | PMID 35681565 Get It

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy characterized by nonspecific presenting symptoms, lack of a screening test, rapidly progressive clinical course, and presentation with an advanced-stage disease in the majority of patients. PDAC is essentially a systemic disease irrespective of the initial stage, as most patients with non-metastatic PDAC undergoing curative-intent treatment eventually experience metastatic relapse. Currently, cytotoxic chemotherapy remains the cornerstone of treatment in patients with advanced disease. However, the current standard treatment with multiagent chemotherapy has modest efficacy and results in median overall survival (OS) of less than a year and a 5-year OS of about 10%. The pathobiology of PDAC poses many challenges, including a unique tumor microenvironment interfering with drug delivery, intratumoral heterogeneity, and a strongly immunosuppressive microenvironment that supports cancer growth. Recent research is exploring a wide range of novel therapeutic targets, including genomic alterations, tumor microenvironment, and tumor metabolism. The rapid evolution of tumor genome sequencing technologies paves the way for personalized, targeted therapies. The present review summarizes the current chemotherapeutic treatment paradigm of advanced PDAC and discusses the evolving novel targets that are being investigated in a myriad of clinical trials.
Review 2: "SARS-CoV-2 Can Infect Human Embryos"
Chakraborty, Rana

Mayo Clinic

No container title available | May 24, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1162/2e3983f5.0a51c141 Get It

Reviews of "SARS-CoV-2 Can Infect Human Embryos"
Piedimonte, Giovanni , Chakraborty, Rana

Mayo Clinic

No container title available | May 24, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1162/2e3983f5.13264347 Get It

Evolving Role of Adjuvant Systemic Therapy for Kidney and Urothelial Cancers
Niglio, Scot A. , Simon, Nicholas I. , Maskens, Deborah , Weinstock, Chana , Apolo, Andrea B , Msaouel, Pavlos , Chandran, Elias B. A. , Perez, Gabriela, Ballman, Karla V.

Mayo Clinic

American Society of Clinical Oncology Educational Book | May 24, 2022 | Volume: No volume available | Issue: 42 | Pages: 311-326

10.1200/edbk_350829 | PMID 35609225 Get It

The role of adjuvant therapy in renal cell carcinoma and urothelial carcinoma is rapidly evolving. To date, the U.S. Food and Drug Administration has approved sunitinib and pembrolizumab in the adjuvant setting for renal cell carcinoma and nivolumab for urothelial carcinoma based on disease-free survival benefit. The U.S. Food and Drug Administration held a joint workshop with the National Cancer Institute and the Society of Urologic Oncology in 2017 to harmonize design elements, including eligibility and radiologic assessments across adjuvant trials in renal cell carcinoma and urothelial carcinoma. Considerations from the discussion at these workshops led the U.S. Food and Drug Administration to draft guidances to help inform subsequent adjuvant trial design for renal cell carcinoma and urothelial carcinoma. Patient-centered decision-making is crucial when determining therapeutic choices in the adjuvant setting; utility functions can be used to help quantify each patient’s goals, values, and risk/benefit trade-offs to ensure that the decision regarding adjuvant therapy is informed by their preferences and the evolving outcomes data.
Durotaxis in Lung Fibrosis: Transitioning from In Vitro Mechanisms to In Vivo Imaging
Ganzleben, I., Chrysovergi, Maria-Anna , Al-Hilal, T.A., Liu, F., Santos, Ana , Vincent, Lauren, Happe, Cassandra, Yates, Charles R. , Mempel, Thorsten R. , Engler, Anne-Marie, Tschumperlin, Daniel J. , Chaum, Edward , Engler, A.J., Lagares, David

Mayo Clinic

A60. PULMONARY FIBROSIS: ANIMAL AND CELL CULTURE MODELS | May 24, 2022 | Volume: No volume available | Issue: No issue available | Pages: A5551-A5551

10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a5551 Get It

A Machine Learning Algorithm Outperforms Traditional Multiple Regression to Predict Risk of Unplanned Overnight Stay Following Outpatient Medial Patellofemoral Ligament Reconstruction
Ezuma, Chimere O. , Lu, Yining , Pareek, Ayoosh , Wilbur, Ryan R. , Krych, Aaron J. , Wilbur, Ryan, Lu, Yining , Krych, Aaron J , Forsythe, Brian , Camp, Christopher L.

Mayo Clinic

Arthroscopy, Sports Medicine, and Rehabilitation | May 24, 2022 | Volume: 4 | Issue: 3 | Pages: No page available

10.1016/j.asmr.2022.03.009 | PMID 35747652 Get It

Purpose To determine whether conventional logistic regression or machine learning algorithms were more precise in identifying the risk factors for unplanned overnight admission after medial patellofemoral ligament (MPFL) reconstruction. Methods A retrospective review of the prospectively collected National Surgical Quality Improvement Program database was performed to identify patients who underwent outpatient MPFL reconstruction from 2006–2018. Patients admitted overnight were identified as those with length of stay of 1 or more days. Models were generated using random forest, extreme gradient boosting, adaptive boosting, or elastic net penalized logistic regression, and an additional model was produced as a weighted ensemble of the 4 final algorithms. The predictive capacity of these models was compared to that of logistic regression. Results Of the 1307 patients identified, 221 (16.9%) required at least one overnight stay after MPFL reconstruction. Multivariate logistic regression found the following variables to be predictors of inpatient admission: age (odds ratio [OR] = 1.03 [95% confidence interval {CI} 1.02‐1.04]; P <.001), spinal anesthesia (OR = 3.42 [95% CI 1.98‐6.08]; P < .001), American Society of Anesthesiologists (ASA) class 3/4 (OR = 1.96 [95% CI 1.25‐3.06]; P < .001), history of chronic obstructive pulmonary disease (COPD) (OR = 6.44 [95% CI 1.58‐26.17]; P = .02), and body mass index (BMI) (OR = 1.03 [95% CI 1.01‐1.05]; P < .001). The ensemble model achieved the best performance based on discrimination assessed via internal validation (area under the curve = 0.722). The variables determined most important by the ensemble model were increasing BMI, increasing age, ASA class, anesthesia, smoking, hypertension, lateral release, and history of COPD. Conclusions An internally validated machine learning algorithm outperformed logistic regression modeling in predicting the need for unplanned overnight hospitalization after MPFL reconstruction. In this model, the most significant risk factors for admission were age, BMI, ASA class, smoking status, hypertension, lateral release, and history of COPD. This tool can be deployed to augment provider assessment to identify high‐risk candidates and appropriately set postoperative expectations for patients. Clinical Relevance Identifying and mitigating patient risk factors to prevent adverse surgical outcomes and hospitalizations is one of our primary goals. There may be a key role for machine learning algorithms to help successfully and efficiently risk stratify patients to decrease costs, appropriately set postoperative expectations, and increase the quality of delivered care.
Six-Minute Walk Distance Predicts Outcomes in a Cohort of Liver Transplant Candidates
Cox, Katherine , Moutchia, Jude , Krowka, Michael J. , Fallon, Michael B. , Al‐Naamani, Nadine , Kawut, Steven M. , Ventetuolo, Corey E.

Mayo Clinic

B54. PACIFIC HEIGHTS: BIOMARKERS AND QUALITY OF LIFE IN PULMONARY HYPERTENSION | May 24, 2022 | Volume: No volume available | Issue: No issue available | Pages: A5640-A5640

10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a5640 Get It

Radiomics Based Classification of Pulmonary Nodules Into Adeno - and Non-Adenocarcinomas, Virtual Lung Biopsy
Al-Ghoula, F., Rajagopalan, Srinivas, Clay, RD., Peikert, Tobias, Rajagopalan, Srinivasan , Clay, Ryan , Bartholmai, Brian J.

Mayo Clinic

B30. THE QUEST FOR THE HOLY GRAIL: MODELING AND BIOMARKERS FOR NODULES AND LUNG CANCER | May 24, 2022 | Volume: No volume available | Issue: No issue available | Pages: A5588-A5588

10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a5588 Get It

Risk-Based Lung Cancer Screening in the Mayo Clinic Lung Screening Program
Midthun, David E. , Sykes, Anne Marie G., Ingalls, Lori A, Deetz, Daniel C, Degen, Susanne C, Glantz, Janel N, Taji, Jamil, Swanson, Kirsten, Jensen, Eric A., Pappagallo, Laura C, Johnson, Margaret M. , McComb, Barbara L., Loosbrock, Lynn M., Rode, Matthew M. , Allen, Mark S. , Deetz, Daniel C., Degen, Susanne C., Glantz, Janel N., Yang, Ping

Mayo Clinic

B30. THE QUEST FOR THE HOLY GRAIL: MODELING AND BIOMARKERS FOR NODULES AND LUNG CANCER | May 24, 2022 | Volume: No volume available | Issue: No issue available | Pages: A5587-A5587

10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a5587 Get It